Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
John Zhang
Institution:
Tango Therapeutics (United States)
Observed institution:
Tango Therapeutics (United States)
ORCID:
0009-0004-4172-140X
Observed ORCID:
0009-0004-4172-140X
OpenAlex ID:
A5133988145
TNG961 Is a Selective Oral HBS1L Molecular Glue Degrader for the Treatment of FOCAD- Deleted Cancers
2026
·
Hilary E. Nicholson
, Douglas A. Whittington
, et al.
·
Cancer Discovery
·
3
Table S4 from TNG961 Is a Selective Oral HBS1L Molecular Glue Degrader for the Treatment of FOCAD-Deleted Cancers
2026
·
Hilary E. Nicholson
, Douglas A. Whittington
, et al.
Figure S3 from TNG961 Is a Selective Oral HBS1L Molecular Glue Degrader for the Treatment of FOCAD-Deleted Cancers
2026
·
Hilary E. Nicholson
, Douglas A. Whittington
, et al.
Table S1 from TNG961 Is a Selective Oral HBS1L Molecular Glue Degrader for the Treatment of FOCAD-Deleted Cancers
2026
·
Hilary E. Nicholson
, Douglas A. Whittington
, et al.
Figure 2 from TNG961 Is a Selective Oral HBS1L Molecular Glue Degrader for the Treatment of FOCAD-Deleted Cancers
2026
·
Hilary E. Nicholson
, Douglas A. Whittington
, et al.
Figure 4 from TNG961 Is a Selective Oral HBS1L Molecular Glue Degrader for the Treatment of FOCAD-Deleted Cancers
2026
·
Hilary E. Nicholson
, Douglas A. Whittington
, et al.
Table S3 from TNG961 Is a Selective Oral HBS1L Molecular Glue Degrader for the Treatment of FOCAD-Deleted Cancers
2026
·
Hilary E. Nicholson
, Douglas A. Whittington
, et al.
Figure 5 from TNG961 Is a Selective Oral HBS1L Molecular Glue Degrader for the Treatment of FOCAD-Deleted Cancers
2026
·
Hilary E. Nicholson
, Douglas A. Whittington
, et al.
Figure 7 from TNG961 Is a Selective Oral HBS1L Molecular Glue Degrader for the Treatment of FOCAD-Deleted Cancers
2026
·
Hilary E. Nicholson
, Douglas A. Whittington
, et al.
Figure S1 from TNG961 Is a Selective Oral HBS1L Molecular Glue Degrader for the Treatment of FOCAD-Deleted Cancers
2026
·
Hilary E. Nicholson
, Douglas A. Whittington
, et al.
Supplementary DataSet 1 from TNG961 Is a Selective Oral HBS1L Molecular Glue Degrader for the Treatment of FOCAD-Deleted Cancers
2026
·
Hilary E. Nicholson
, Douglas A. Whittington
, et al.
Data from TNG961 Is a Selective Oral HBS1L Molecular Glue Degrader for the Treatment of FOCAD-Deleted Cancers
2026
·
Hilary E. Nicholson
, Douglas A. Whittington
, et al.
Figure 6 from TNG961 Is a Selective Oral HBS1L Molecular Glue Degrader for the Treatment of FOCAD-Deleted Cancers
2026
·
Hilary E. Nicholson
, Douglas A. Whittington
, et al.
Figure S7 from TNG961 Is a Selective Oral HBS1L Molecular Glue Degrader for the Treatment of FOCAD-Deleted Cancers
2026
·
Hilary E. Nicholson
, Douglas A. Whittington
, et al.
Table S2 from TNG961 Is a Selective Oral HBS1L Molecular Glue Degrader for the Treatment of FOCAD-Deleted Cancers
2026
·
Hilary E. Nicholson
, Douglas A. Whittington
, et al.
Figure 3 from TNG961 Is a Selective Oral HBS1L Molecular Glue Degrader for the Treatment of FOCAD-Deleted Cancers
2026
·
Hilary E. Nicholson
, Douglas A. Whittington
, et al.
Figure 1 from TNG961 Is a Selective Oral HBS1L Molecular Glue Degrader for the Treatment of FOCAD-Deleted Cancers
2026
·
Hilary E. Nicholson
, Douglas A. Whittington
, et al.
Figure S4 from TNG961 Is a Selective Oral HBS1L Molecular Glue Degrader for the Treatment of FOCAD-Deleted Cancers
2026
·
Hilary E. Nicholson
, Douglas A. Whittington
, et al.
Figure S5 from TNG961 Is a Selective Oral HBS1L Molecular Glue Degrader for the Treatment of FOCAD-Deleted Cancers
2026
·
Hilary E. Nicholson
, Douglas A. Whittington
, et al.
Figure S6 from TNG961 Is a Selective Oral HBS1L Molecular Glue Degrader for the Treatment of FOCAD-Deleted Cancers
2026
·
Hilary E. Nicholson
, Douglas A. Whittington
, et al.
Figure S2 from TNG961 Is a Selective Oral HBS1L Molecular Glue Degrader for the Treatment of FOCAD-Deleted Cancers
2026
·
Hilary E. Nicholson
, Douglas A. Whittington
, et al.
Abstract ND03: TNG961: A selective oral molecular glue degrader of HBS1L for the treatment of FOCAD-deficient cancers
2026
·
Douglas A. Whittington
, Frank J. Bruzzese
, et al.
·
Cancer Research
Show more works
View as search
Works count:
22
Citation count:
3
H-index:
1
I10-index:
Year
Topic
Type